Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 3:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 600 matching trials from the live ClinicalTrials.gov search.
Conditions
Osteoporosis
Interventions
LY2541546, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 85 Years · Female only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Gainesville, Georgia • Bethesda, Maryland
Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
SGLT-2 inhibitor, SGLT2 inhibitor
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
8 Years to 18 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration

NCT04026256
Conditions
Postmenopausal Osteoporosis
Interventions
Teriparatide, Denosumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Terminated Not applicable Interventional Results available

Stem Cell Recruitment in Osteoporosis Therapy

NCT01656629
Conditions
Low Bone Density
Interventions
Teriparatide, Alendronate, calcium and vitamin D
Drug · Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 80 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Not applicable Interventional Results available

Vitamin D Supplements for HIV-positive Patients on cART

NCT01295034
Conditions
HIV-associated Co-morbidities
Interventions
conventional vitamin D treatment, tiered/titrated vitamin D dosing
Dietary Supplement · Drug
Lead sponsor
Andrea Branch
Other
Eligibility
18 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Active, not recruiting Phase 2 Interventional

Study of UC-MSC in DMD Patients

NCT06579352
Conditions
Duchenne Muscular Dystrophy
Interventions
Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC)
Biological
Lead sponsor
MED Institute Inc.
Industry
Eligibility
5 Years to 10 Years · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Dallas, Texas • Flower Mound, Texas
Completed Phase 2 Interventional Accepts healthy volunteers

Treatment of Calcium Deficiency in Young Women

NCT00000426
Conditions
Osteoporosis
Interventions
Calcium supplement
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 27 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2000
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Type 2 Diabetes
Interventions
Sitagliptin
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Columbia, Missouri
Completed Phase 2 Interventional Results available

Sildenafil for Treatment of Choroidal Ischemia

NCT04356716
Conditions
Choroidal Ischemia, Vitelliform Macular Dystrophy, Age-related Macular Degeneration, Central Serous Retinopathy, Retinitis Pigmentosa
Interventions
Sildenafil, Standard of Care Sildenafil, Ocular Coherence Tomography-Angiography (OCT-A), Visual Acuity (VA)
Drug · Other · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Osteoporosis
Interventions
Pamidronate
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
5 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Osteopetrosis
Interventions
rhPTH
Drug
Lead sponsor
University of Chicago
Other
Eligibility
20 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Osteoporosis
Interventions
Vitamin D
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
25 Years to 75 Years · Female only
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Bone Density, Bone Loss, Anorexia Nervosa, Eating Disorder, Atypical Anorexia Nervosa
Interventions
Denosumab 60 MG [Prolia], Placebo Injection, Alendronate 70Mg Tab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Completed No phase listed Observational Accepts healthy volunteers Results available

Do Serotonin Reuptake Inhibitors (SSRIs) Affect Bone Mass in Adolescents

NCT02147184
Conditions
The Skeletal Effects of SSRIs
Interventions
Not listed
Lead sponsor
Chadi A. Calarge
Other
Eligibility
15 Years to 20 Years
Enrollment
287 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy

NCT01207908
Conditions
Duchenne Muscular Dystrophy
Interventions
IGF-1
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Bone Mineral Density, Hemophilia A, Hemophilia B
Interventions
DXA scan + MRI
Other
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
25 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Completed Phase 3 Interventional Results available

The Effect Of Oral Ibandronate In Male Osteoporosis

NCT00397839
Conditions
Male Osteoporosis
Interventions
Ibandronate, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
30 Years and older · Male only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 36 more
Completed No phase listed Observational Accepts healthy volunteers

Bone and Vascular Health in Postmenopausal Women With Type 1 Diabetes

NCT02693964
Conditions
Diabetes Mellitus, Type 1
Interventions
Bone density and carotid ultrasound
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
45 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Duchenne Muscular Dystrophy
Interventions
delandistrogene moxeparvovec
Genetic
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
Male only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
22
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 19 more
Conditions
Multiple Sclerosis, Low Bone Density
Interventions
Copaxone, Interferon-beta 1a, Interferon-beta 1b
Drug
Lead sponsor
Nancy Hammond, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Kansas City, Kansas
Conditions
Bone Mineral Density, Bone Strength
Interventions
LMHF mechanical stimulation active device, LMHF mechanical stimulation placebo device
Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
7 Years to 17 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Cystic Fibrosis, Hypoestrogenism
Interventions
Transdermal estrogen, Progesterone
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
0 Years to 100 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Leukemia, Lymphoblastic, Acute, Osteoporosis
Interventions
Calcium carbonate (Tums), vitamin D, Placebo
Drug · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
3
States / cities
Memphis, Tennessee
Conditions
Muscular Dystrophy, Duchenne
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
5 Years to 13 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina